宫颈癌组织中KGFR、TFPI-2的表达及临床意义
|
摘要
目的探讨宫颈癌组织中角质细胞生长因子受体(KGFR)、组织因子途径抑制物-2(TFPI-2)的表达以及临床意义。方法选取2016年1月至2018年1月我院保存的宫颈癌组织标本56例(宫颈癌组),同时选取正常宫颈组织35例作为对照组,采用免疫组化染色法检测KGFR和TFPI-2表达。结果宫颈癌组KGFR阳性表达率为73.21%,明显高于对照组(P<0.05),而TFPI-2阳性表达率为28.57%,明显低于对照组(P<0.05);宫颈癌TNM分期Ⅲ期患者KGFR阳性表达率为100.00%,明显高于Ⅰ～Ⅱ期患者(P<0.05),而TFPI-2阳性表达率为0.00%,明显低于Ⅰ～Ⅱ期患者(P<0.05);宫颈癌中低分化患者KGFR阳性表达率为85.37%,明显高于高分化患者(P<0.05);宫颈癌有淋巴结转移患者TFPI-2阳性表达率为5.88%,明显低于无淋巴结转移患者(P<0.05);KGFR与TFPI-2表达呈负相关(rs=-0.599,P<0.05)。结论宫颈癌组织中KGFR表达上调,而TFPI-2表达下调,两者水平与患者临床病理特征有一定关系,且两者间有一定相关性。
Objective To investigate the expression and clinical significance of keratinocyte growth factor receptor (KGFR) and tissue factor pathway inhibitor-2(TFPI-2) in cervical cancer. Methods A total of 56 specimens of cervical cancer(cervical cancer group) in our hospital from January 2016 to January 2018 were selected and 35 cases of normal cervix tissues were selected as the control group,the expression of KGFR and TFPI-2 were detected by immunohistochemical staining. Results The positive expression rate of KGFR in cervical cancer group was 73.21%,which was significantly higher than that in the control group(P<0.05),while the positive expression rate of TFPI-2 was 28.57%,which was significantly lower than that in the control group(P<0.05);The positive expression rate of KGFR in TNM stage Ⅲ of cervical cancer was 100.00%,which was significantly higher than that in stage I to II patients(P<0.05),while the positive rate of TFPI-2 was 0.00%,which was significantly lower than that in stage I to II patients(P<0.05);The positive expression rate of KGFR in poorly and middle differentiated cervical cancer was 85.37%,which was significantly higher than that in patients with high differentiation(P<0.05);The positive expression rate of TFPI-2 in cervical cancer patients with lymph node metastasis was 5.88%,which was significantly lower than that in patients without lymph node metastasis(P<0.05);There was a negative correlation between KGFR and TFPI-2 expression(rs=-0.599,P<0.05). Conclusion The expression of KGFR is up-regulated and TFPI-2 is down-regulated in cervical cancer tissues,the expressions of them are correlated with clinicopathological features.
Objective To investigate the expression and clinical significance of keratinocyte growth factor receptor (KGFR) and tissue factor pathway inhibitor-2(TFPI-2) in cervical cancer. Methods A total of 56 specimens of cervical cancer(cervical cancer group) in our hospital from January 2016 to January 2018 were selected and 35 cases of normal cervix tissues were selected as the control group,the expression of KGFR and TFPI-2 were detected by immunohistochemical staining. Results The positive expression rate of KGFR in cervical cancer group was 73.21%,which was significantly higher than that in the control group(P<0.05),while the positive expression rate of TFPI-2 was 28.57%,which was significantly lower than that in the control group(P<0.05);The positive expression rate of KGFR in TNM stage Ⅲ of cervical cancer was 100.00%,which was significantly higher than that in stage I to II patients(P<0.05),while the positive rate of TFPI-2 was 0.00%,which was significantly lower than that in stage I to II patients(P<0.05);The positive expression rate of KGFR in poorly and middle differentiated cervical cancer was 85.37%,which was significantly higher than that in patients with high differentiation(P<0.05);The positive expression rate of TFPI-2 in cervical cancer patients with lymph node metastasis was 5.88%,which was significantly lower than that in patients without lymph node metastasis(P<0.05);There was a negative correlation between KGFR and TFPI-2 expression(rs=-0.599,P<0.05). Conclusion The expression of KGFR is up-regulated and TFPI-2 is down-regulated in cervical cancer tissues,the expressions of them are correlated with clinicopathological features.
引文
[1]Zhu Y,Yang J,Zhang X,et al.Acquired treatment response from neoadjuvant chemotherapy predicts a favorable prognosis for local advanced cervical cancer[J].Medicine,2018,97(17):530-532.
[2]Huang M,Chen Q,Xiao J,et al.Overexpression of Hypoxia-Inducible Factor-1αIs a Predictor of Poor Prognosis in Cervical Cancer[J].Int J Gynecol Cancer,2014,24(6):1054-1064.
[3]李娜,熊娇,史明媚,等.宫颈癌组织中组织因子途径抑制物-2表达变化及其与VEGF表达、微血管密度的相关性[J].山东医药,2018,58(3):59-61.
[4]庄建发,纪荣佳,唐娅,等.组织因子途径抑制剂2在胃癌中表达的临床意义及其预后分析[J].中国肿瘤临床与康复,2014,21(3):264-266.
[5]张鲁川,王峰,樊青霞.TFPI-2和MMP-9在食管鳞状细胞癌组织中的表达及其与血管生成拟态的关系[J].吉林大学学报:医学版,2014,40(3):664-667.
[6]幸琼,幸情.HR-HPV与TCT筛查宫颈癌及其癌前病变的临床价值[J].实验与检验医学,2016,34(6):761-763.
[7]Ki EY,Lee KH,Park JS,et al.A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer[J].Cancer Res Treat,2016,48(1):266-272.
[8]张莉,张凡.子宫颈癌不同放疗方式的疗效及耐受机制[J].中国老年学杂志,2016,36(15):3742-3744.
[9]王振国,李争,陈瑜.宫颈癌组织中KGF、KGFR及MMP-9的表达变化[J].山东医药,2016,56(19):50-52.
[10]王凤记,王庆宝.TFPI-2与消化道恶性肿瘤关系的研究进展[J].泰山医学院学报,2014,35(4):337-340.
[11]杨素荣,张瑞莲,郭莉娜,等.妇科恶性肿瘤术后深静脉血栓形成患者组织因子及其途径抑制物的检测及意义[J].潍坊医学院学报,2015,25(4):298-299.
[12]沈振华,于峰,唐晓永,等.黔南地区苗族与汉族早期宫颈癌患者临床病理特点和预后影响因素[J].中国妇幼保健,2014,29(22):3564-3566.
[13]梁聪,李维丽,陈春林,等.基于中国大陆部分医院宫颈癌诊疗大数据的嗜神经浸润与临床病理参数相关性分析[J].中国实用妇科与产科杂志,2018,34(1):72-77.
[14]孙彦珍.组织因子途径抑制物-2在宫颈上皮内肿瘤和宫颈鳞癌中的表达[J].中国妇幼保健,2015,30(34):6139-6140.
[15]Seabra M,Candido E,Vidigal P,et al.Immunohistochemical WWOX Expression and Association with Angiogenesis,p53 Expression,Cell Proliferation and Clinicopathological Parameters in Cervical Cancer[J].Rev Bras Ginecol Obstet,2018,40(2):79-85.()
[2]Huang M,Chen Q,Xiao J,et al.Overexpression of Hypoxia-Inducible Factor-1αIs a Predictor of Poor Prognosis in Cervical Cancer[J].Int J Gynecol Cancer,2014,24(6):1054-1064.
[3]李娜,熊娇,史明媚,等.宫颈癌组织中组织因子途径抑制物-2表达变化及其与VEGF表达、微血管密度的相关性[J].山东医药,2018,58(3):59-61.
[4]庄建发,纪荣佳,唐娅,等.组织因子途径抑制剂2在胃癌中表达的临床意义及其预后分析[J].中国肿瘤临床与康复,2014,21(3):264-266.
[5]张鲁川,王峰,樊青霞.TFPI-2和MMP-9在食管鳞状细胞癌组织中的表达及其与血管生成拟态的关系[J].吉林大学学报:医学版,2014,40(3):664-667.
[6]幸琼,幸情.HR-HPV与TCT筛查宫颈癌及其癌前病变的临床价值[J].实验与检验医学,2016,34(6):761-763.
[7]Ki EY,Lee KH,Park JS,et al.A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer[J].Cancer Res Treat,2016,48(1):266-272.
[8]张莉,张凡.子宫颈癌不同放疗方式的疗效及耐受机制[J].中国老年学杂志,2016,36(15):3742-3744.
[9]王振国,李争,陈瑜.宫颈癌组织中KGF、KGFR及MMP-9的表达变化[J].山东医药,2016,56(19):50-52.
[10]王凤记,王庆宝.TFPI-2与消化道恶性肿瘤关系的研究进展[J].泰山医学院学报,2014,35(4):337-340.
[11]杨素荣,张瑞莲,郭莉娜,等.妇科恶性肿瘤术后深静脉血栓形成患者组织因子及其途径抑制物的检测及意义[J].潍坊医学院学报,2015,25(4):298-299.
[12]沈振华,于峰,唐晓永,等.黔南地区苗族与汉族早期宫颈癌患者临床病理特点和预后影响因素[J].中国妇幼保健,2014,29(22):3564-3566.
[13]梁聪,李维丽,陈春林,等.基于中国大陆部分医院宫颈癌诊疗大数据的嗜神经浸润与临床病理参数相关性分析[J].中国实用妇科与产科杂志,2018,34(1):72-77.
[14]孙彦珍.组织因子途径抑制物-2在宫颈上皮内肿瘤和宫颈鳞癌中的表达[J].中国妇幼保健,2015,30(34):6139-6140.
[15]Seabra M,Candido E,Vidigal P,et al.Immunohistochemical WWOX Expression and Association with Angiogenesis,p53 Expression,Cell Proliferation and Clinicopathological Parameters in Cervical Cancer[J].Rev Bras Ginecol Obstet,2018,40(2):79-85.()